<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02836639</url>
  </required_header>
  <id_info>
    <org_study_id>BEB</org_study_id>
    <nct_id>NCT02836639</nct_id>
  </id_info>
  <brief_title>BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Phase II Study for Safety and Efficacy of BEB (Bendamustine, Etoposide, Busulfan) Conditioning Regimen for ASCT in Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pusan National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II study for safety and efficacy of BEB (Bendamustine, Etoposide, Busulfan)
      conditioning regimen for ASCT in non-Hodgkin's lymphoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year after ASCT</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years after ASCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year and 3 year after ASCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>1 year and 3 year after ASCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>1 year and 3 year after ASCT</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Busulfan, Etoposide, Bendamustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive the conditioning regimen followed by autologous stem cell transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Busulfan 0.8 mg/kg four times per day from day -7 to day -5</description>
    <arm_group_label>Busulfan, Etoposide, Bendamustine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide 400 mg/m2 from day -5 to day -4</description>
    <arm_group_label>Busulfan, Etoposide, Bendamustine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Bendamustine 200 mg/m2 starting dose on day -3 and -2</description>
    <arm_group_label>Busulfan, Etoposide, Bendamustine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically diagnosed non-Hodgkin's lymphoma

          2. 16 ≤ Age ≤ 65 years

          3. Adequate cardiac function with cardiac ejection fraction greater than 50% by
             echocardiogram or multiple gated acquisition scan(MUGA)

          4. Adequate kidney function with serum creatinine&lt; 2.0 mg/dL

          5. Adequate liver function with /serum bilirubin lower than 2 times the normal upper
             limit, Aspartate aminotransferase(AST)/ Alanine aminotransaminase(ALT) lower than 3
             times the normal upper limit. In case of DLBCL liver invasion; serum bilirubin lower
             than 5 times the normal upper limit, AST/ALT lower than 5 times the normal upper
             limit.

          6. Adequate bone marrow function with absolute neutrophil count ≥ 1,500/µL; platelets ≥
             75,000/µL; hemoglobin ≥ 9.0 g/dL

          7. Patients who voluntarily gave informed consent before performing any test that is not
             part of routine care of patients

          8. Candidate for ASCT

        Exclusion Criteria:

          1. Positive serology for HIV, hepatitis C virus(HCV) If the hepatitis B virus(HBV)
             patient was administrated prophylactic antiviral agents. It would be eligible
             following the judgment of the investigator

          2. Pregnant or breast-feeding. Females of childbearing potential who do not agree to
             undergo pregnancy tests or repeated use effective birth control while included in the
             clinical trial.

          3. Patients with serious or uncontrolled medical condition; 1) Abnormalities in cardiac
             function or clinically significant heart disease such as congestive heart failure,
             arrhythmia, unstable angina with treatment within 6 months or acute myocardial
             infarction; 2) Previous history of serious neurological or psychiatric disease; 3)
             Acute, severe active infection requiring immediate treatment(Virus, Bacteria, Fungal
             infection); 4) chronic obstructive pulmonary disease requiring oral steroid therapy or
             Forced expiratory volume 1 sec(FEV1)&lt;0.8 L less than the test of pulmonary function at
             rest; 5) If there are other diseases that are deemed inappropriate as a target of the
             present clinical trial following the Investigator's judgment; 6) Congenital or
             acquired bleeding disorders

          4. Patients receiving any other investigational systemic therapy (Hormone, Immune,
             chemotherapy)

          5. Allergic to the investigational drug

          6. Patients who have difficulty understanding the informed consent form or patients who
             did not give consent

          7. Serum bilirubin upper than 2 times the normal upper limit

          8. Major surgery procedure within 30 days prior to start of investigational treatment

          9. Patients vaccinated against yellow fever
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hojin Shin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National Universty Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jieon Lee</last_name>
    <phone>+82-51-240-7053</phone>
    <email>jieon@pnuh.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hojin Shin</last_name>
      <email>hojinja@hanmail.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Giardini C, Falcioni S, Cuberli F, Gobbi M, Sarina B, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Isidori A. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011 Sep 22;118(12):3419-25. doi: 10.1182/blood-2011-04-351924. Epub 2011 Aug 3.</citation>
    <PMID>21816830</PMID>
  </reference>
  <reference>
    <citation>Shin HJ, Lee WS, Lee HS, Kim H, Lee GW, Song MK, Kim JS, Yhim HY, Chung JS. Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2014 Nov;55(11):2490-6. doi: 10.3109/10428194.2014.882504. Epub 2014 Mar 7.</citation>
    <PMID>24432893</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2016</study_first_submitted>
  <study_first_submitted_qc>July 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2016</study_first_posted>
  <last_update_submitted>July 14, 2016</last_update_submitted>
  <last_update_submitted_qc>July 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pusan National University Hospital</investigator_affiliation>
    <investigator_full_name>Ho-Jin Shin</investigator_full_name>
    <investigator_title>Professor department of hematooncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

